The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart
Open Access
- 1 January 2016
- journal article
- review article
- Published by Wiley in Journal of Immunology Research
- Vol. 2016, 1-12
Abstract
Accumulating evidence reveals involvement of T lymphocytes and adaptive immunity in the chronic inflammation associated with infectious and noninfectious diseases of the heart, including coronary artery disease, Kawasaki disease, myocarditis, dilated cardiomyopathies, Chagas, hypertensive left ventricular (LV) hypertrophy, and nonischemic heart failure. Chemokine CXCL10 is elevated in cardiovascular diseases, along with increased cardiac infiltration of proinflammatory Th1 and cytotoxic T cells. CXCL10 is a chemoattractant for these T cells and polarizing factor for the proinflammatory phenotype. Thus, targeting the CXCL10 receptor CXCR3 is a promising therapeutic approach to treating cardiac inflammation. Due to biased signaling CXCR3 also couples to anti-inflammatory signaling and immunosuppressive regulatory T cell formation when activated by CXCL11. Numbers and functionality of regulatory T cells are reduced in patients with cardiac inflammation, supporting the utility of biased agonists or biologicals to simultaneously block the pro-inflammatory and activate the anti-inflammatory actions of CXCR3. Other immunotherapy strategies to boost regulatory T cell actions include intravenous immunoglobulin (IVIG) therapy, adoptive transfer, immunoadsorption, and low-dose interleukin-2/interleukin-2 antibody complexes. Pharmacological approaches include sphingosine 1-phosphate receptor 1 agonists and vitamin D supplementation. A combined strategy of switching CXCR3 signaling from pro- to anti-inflammatory and improving Treg functionality is predicted to synergistically lessen adverse cardiac remodeling.Keywords
Funding Information
- University of Mississippi (100410)
- American University of Beirut (100410)
- European Research Council (100410)
- British Heart Foundation (100410)
This publication has 158 references indexed in Scilit:
- CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implicationsCytokine & Growth Factor Reviews, 2011
- Three 4-letter words of hypertension-related cardiac hypertrophy: TRPC, mTOR, and HDACJournal of Molecular and Cellular Cardiology, 2011
- Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditisJournal of Autoimmunity, 2011
- Natural Regulatory T Cells Control Coronary Arteriolar Endothelial Dysfunction in Hypertensive MiceThe American Journal of Pathology, 2011
- CXCR3-dependent accumulation and activation of perivascular macrophages is necessary for homeostatic arterial remodeling to hemodynamic stressesJournal of Experimental Medicine, 2010
- Chagas diseaseThe Lancet, 2010
- CD4+ T‐cell localization to the large intestinal mucosa during Trichuris muris infection is mediated by Gαi‐coupled receptors but is CCR6‐ and CXCR3‐independentImmunology, 2010
- Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in ratsInternational Journal of Experimental Pathology, 2008
- Ticks produce highly selective chemokine binding proteins with antiinflammatory activityJournal of Experimental Medicine, 2008
- Inhibition of Gαi2 Activation by Gαi3 in CXCR3-mediated SignalingJournal of Biological Chemistry, 2007